首页> 美国卫生研究院文献>other >Phase 1–2 study of docetaxel plus aflibercept in patients with recurrent ovarian primary peritoneal or fallopian tube cancer

【2h】

Phase 1–2 study of docetaxel plus aflibercept in patients with recurrent ovarian primary peritoneal or fallopian tube cancer

机译：相1-2患者复发卵巢原发性腹膜或输卵管癌多西紫杉醇联合阿柏西普的研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 other
作者
Robert L Coleman; Linda R Duska; Pedro T Ramirez; John V Heymach; Aparna A Kamat; Susan C Modesitt; Kathleen M Schmeler; Revathy B Iyer; Michael E Garcia; Debbie L Millera; Edward F Jackson; Chaan S Ng; Vikas Kundra; Robert Jaffe; Anil K Sood;
展开▼
作者单位

展开▼
年(卷),期 -1(12),12
年度 -1
页码 1109–1117
总页数 19
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. [J] . Coleman RL, Duska LR, Ramirez PT, The lancet oncology . 2011,第12期

机译：多西他赛加阿柏西普在复发性卵巢癌，原发性腹膜癌或输卵管癌患者中的1-2期研究。
2. Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904 [J] . ColemanR.L., MoonJ., SoodA.K., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2014,第9期

机译：多西紫杉醇联合凡德他尼与多西紫杉醇再加凡德他尼治疗持续或复发的上皮性卵巢癌，输卵管癌或原发性腹膜癌的II期随机研究：SWOG S0904
3. Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904 [J] . ColemanR.L., MoonJ., SoodA.K., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2014,第9期

机译：Docetaxel Plus Vandetanib的随机阶段II研究与Docetaxel一起进行，然后是Vandetanib患者持续或复发上皮卵巢卵巢，输卵管或原发性腹膜癌：Swog S0904
4. Morphologic 3D scanning of fallopian tubes to assist ovarian cancer diagnosis [C] . Wendy-Julie Madore, Etienne De Montigny, Andreanne Deschenes, Photonic therapeutics and diagnostics XII . 2016

机译：输卵管的形态3D扫描有助于卵巢癌诊断
5. Analysis of Oncologic Outcomes Associated with Anti-adhesion Sodium Hyaluronate-Carboxymethylcellulose Barrier Following Optimal or Complete Cytoreductive Surgery for Ovarian, Fallopian Tube, and Peritoneal Cancers. [D] . Krill, Lauren. 2014

机译：卵巢癌，输卵管癌和腹膜癌的最佳或完全细胞还原手术后，与抗粘连透明质酸钠-羧甲基纤维素屏障相关的肿瘤学结果分析。
6. Randomized Phase II Study of Docetaxel Plus Vandetanib vs. Docetaxel Followed by Vandetanib in Patients with Persistent or Recurrent Epithelial Ovarian Fallopian Tube or Primary Peritoneal Carcinoma: SWOG S0904 [O] . Robert L. Coleman, James Moon, Anil K. Sood, -1

机译：多西他赛加万德他尼与多西他赛再加万地他尼用于持续性或复发性上皮性卵巢癌输卵管或原发性腹膜癌患者的随机II期研究：SWOG S0904
7. Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results [O] . Jermaine I. Coward, Minal A. Barve, Ganessan Kichenadasse, 2021

机译：腹膜内癌症，持续性或复发性卵巢癌，输卵管癌症或原发性腹膜癌患者的最大耐受剂量和抗肿瘤活性：阶段研究结果

Phase 1–2 study of docetaxel plus aflibercept in patients with recurrent ovarian primary peritoneal or fallopian tube cancer

著录项

相似文献

相关主题

期刊订阅